May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
In vitro Comparison of Cytoprotective Effect and Antioxidative Properties Between Latanoprost, Travoprost and Bimatoprost
Author Affiliations & Notes
  • J.–M. Guenoun
    Quinze–Vingts National Ophthalmology Hospital and INSERM U 598, Paris, France
  • C. Baudouin
    Quinze–Vingts National Ophthalmology Hospital and INSERM U 598, Paris, France
  • P. Rat
    Dept. of Toxicology, Faculty of Biological and Pharmacological Sciences, René Descartes University Paris 5 and INSERM U598, Paris, France
  • J.–M. Warnet
    Dept. of Toxicology, Faculty of Biological and Pharmacological Sciences, René Descartes University Paris 5 and INSERM U598, Paris, France
  • F. Brignole–Baudouin
    Dept. of Toxicology, Faculty of Biological and Pharmacological Sciences, René Descartes University Paris 5 and INSERM U598, Paris, France
  • Footnotes
    Commercial Relationships  J. Guenoun, None; C. Baudouin, None; P. Rat, None; J. Warnet, None; F. Brignole–Baudouin, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3773. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.–M. Guenoun, C. Baudouin, P. Rat, J.–M. Warnet, F. Brignole–Baudouin; In vitro Comparison of Cytoprotective Effect and Antioxidative Properties Between Latanoprost, Travoprost and Bimatoprost . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3773.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: In a previous study we showed that the latanoprost, in its commercial presentation, appeared, in vitro, less toxic than the benzalkonium chloride it contained. Therefore we investigate with microplate cytometry if the three antiglaucoma prostanoids, commercially available, could protect in vitro, conjunctiva–derived cells toward benzalkonium chloride (BAC) toxicity and if an antioxidative mechanism could be involved in prostaglandin effects. Methods: Human conjunctiva–derived epithelial cells from Chang cell line were exposed to latanoprost, travoprost and bimatoprost, and to three formulations of benzalkonium chloride (2x10–2 %, 1.5x10–2 % and 0.5x10–2 %) corresponding to the same concentrations contained in the three prostanoid eye drops. Each solution was diluted to 1/10 and applied for 30 minutes. Cellular membrane integrity, cytosolic H2O2, cytosolic O2.– and apoptosis were evaluated using, respectively, Neutral Red, H2DCF–DA, Hydroethidine and Yopro–1 probes. Results: Cellular viability decreased as benzalkonium chloride concentration increased with a concentration–dependent toxicity. Toxicity of latanoprost and travoprost were statistically significantly lower than their respective BAC concentration (p<0.01) while bimatoprost toxicity was not different compared with control. H2O2 detection statistically decreased with cells exposed to latanoprost (p<0.01) and travoprost (p<0.01) and O2.– detection decreased with cells exposed to latanoprost (p<0.01) compared with their corresponding BAC concentration alone. The Yopro–1 test showed a BAC–induced apoptotic effect, which increased with its concentration. Latanoprost and travoprost were responsible for a pro–apoptotic effect compared with control (p<0.01) but lower than their respective preservative concentration with a significant statistical difference (p<0.01). Conclusions: Latanoprost and travoprost are responsible for a protective effect toward benzalkonium chloride toxicity on conjunctiva–derived epithelial cells in vitro, probably related to antioxidative properties. The low toxicity of bimatoprost could not make it possible to reveal a hypothetic antioxidative effect. The reduction of the reactive oxygen species could be related to a diminution of the BAC pro–apoptotic effect.

Keywords: antioxidants • conjunctiva • cell death/apoptosis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×